HK1115632A1 - Methods for the identification of zap-70 interacting molecules and for the purification of zap-70 - Google Patents

Methods for the identification of zap-70 interacting molecules and for the purification of zap-70

Info

Publication number
HK1115632A1
HK1115632A1 HK08105785.0A HK08105785A HK1115632A1 HK 1115632 A1 HK1115632 A1 HK 1115632A1 HK 08105785 A HK08105785 A HK 08105785A HK 1115632 A1 HK1115632 A1 HK 1115632A1
Authority
HK
Hong Kong
Prior art keywords
aminopyrido
zap
pyrimidine ligand
complex
phosphorylated zap
Prior art date
Application number
HK08105785.0A
Other languages
English (en)
Inventor
Ulrich Kruse
Nigel Ramsden
Gerard Drewes
Dirk Eberhard
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Publication of HK1115632A1 publication Critical patent/HK1115632A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
HK08105785.0A 2006-06-01 2008-05-23 Methods for the identification of zap-70 interacting molecules and for the purification of zap-70 HK1115632A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011409A EP1862802B1 (en) 2006-06-01 2006-06-01 Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70

Publications (1)

Publication Number Publication Date
HK1115632A1 true HK1115632A1 (en) 2008-12-05

Family

ID=37075506

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105785.0A HK1115632A1 (en) 2006-06-01 2008-05-23 Methods for the identification of zap-70 interacting molecules and for the purification of zap-70

Country Status (12)

Country Link
US (1) US20120178180A1 (xx)
EP (1) EP1862802B1 (xx)
JP (1) JP4987970B2 (xx)
CN (1) CN101490557B (xx)
AT (1) ATE417274T1 (xx)
AU (1) AU2007267291B2 (xx)
CA (1) CA2653760A1 (xx)
DE (1) DE602006004196D1 (xx)
DK (1) DK1862802T3 (xx)
ES (1) ES2318616T3 (xx)
HK (1) HK1115632A1 (xx)
WO (1) WO2007137867A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5181908B2 (ja) * 2008-08-04 2013-04-10 株式会社島津製作所 質量分析データ解析装置
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US20120172385A1 (en) 2009-09-11 2012-07-05 Richard John Harrison Ortho substituted pyrimidine compounds as jak inhibitors
AR078675A1 (es) 2009-10-20 2011-11-23 Cellzome Ltd Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes.
US20130131043A1 (en) 2010-04-30 2013-05-23 Richard John Harrison Pyrazole compounds as jak inhibitors
US20130281497A1 (en) * 2010-05-21 2013-10-24 University Of Florida Research Foundation, Inc. Macrocyclic compounds and methods of treatment
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
JP2013534233A (ja) 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CA2843195A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
EP2760863A1 (en) 2011-09-20 2014-08-06 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
JP2015500862A (ja) 2011-12-23 2015-01-08 セルゾーム リミティッド キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体
WO2013174895A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
CN108088998B (zh) * 2016-11-23 2019-12-27 四川大学华西医院 一种肺癌筛查试剂盒
CN113030359A (zh) * 2021-01-28 2021-06-25 成都第一制药有限公司 一种益母草注射液中多种指标成分的检测方法及益母草注射液的质量控制方法
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
AU781444B2 (en) * 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
MXPA05009723A (es) * 2003-03-10 2006-02-17 Schering Corp Analisis de ligando.
JP5520433B2 (ja) * 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
JP5058792B2 (ja) * 2004-06-21 2012-10-24 プロティオーム・サイエンシィズ・ピーエルシー スクリーニング方法
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
EP1891446B1 (en) * 2005-06-14 2013-04-10 Cellzome GmbH Process for the identification of novel enzyme interacting compounds
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
EP2364702A3 (en) * 2006-09-05 2012-01-25 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity

Also Published As

Publication number Publication date
DE602006004196D1 (de) 2009-01-22
JP2009539081A (ja) 2009-11-12
EP1862802B1 (en) 2008-12-10
WO2007137867A1 (en) 2007-12-06
ATE417274T1 (de) 2008-12-15
CN101490557A (zh) 2009-07-22
AU2007267291A1 (en) 2007-12-06
CA2653760A1 (en) 2007-12-06
EP1862802A1 (en) 2007-12-05
US20120178180A1 (en) 2012-07-12
ES2318616T3 (es) 2009-05-01
CN101490557B (zh) 2013-08-21
AU2007267291B2 (en) 2013-09-12
JP4987970B2 (ja) 2012-08-01
DK1862802T3 (da) 2009-04-14

Similar Documents

Publication Publication Date Title
HK1115632A1 (en) Methods for the identification of zap-70 interacting molecules and for the purification of zap-70
HK1111218A1 (en) Methods for the identification of pi3k interacting molecules and for the purification of pi3k
Timm et al. Assembly and purification of enzyme‐functionalized DNA origami structures
Dienhart et al. The yeast Aac2 protein exists in physical association with the cytochrome bc 1-COX supercomplex and the TIM23 machinery
CN101675339B (zh) 涉及细胞表面糖基化作用的方法
WO2003039483A3 (en) An enzyme-based system and sensor for measuring acetone
Wei et al. Deep coverage proteomics identifies more low-abundance missing proteins in human testis tissue with Q-exactive HF mass spectrometer
WO2007050979A3 (en) Real time nucleic acid detection in vivo using protein complementation
Salvi et al. Motif analysis of phosphosites discloses a potential prominent role of the Golgi casein kinase (GCK) in the generation of human plasma phospho-proteome
WO2006065960A3 (en) Cationic liposomes comprising a charge neutral compound and a cationic phospholipid
WO2009007719A3 (en) Detection of micro-organisms based on their nad-dependent dna ligase activity
Pokhrel et al. Probing the effect of mutations of asparagine 181 in the D1 subunit of photosystem II
WO2006020766A3 (en) Point source diffusion cell activity assay apparatuses and methods
WO2006110748A3 (en) Response gene to complement 32 (rgc-32) in disease
EP1243659A4 (en) METHOD FOR DETECTION OF TARGET NUCLEOTIDE SEQUENCES
WO2010056681A3 (en) Thyroid analyte detection and measurement
WO2005059163A3 (en) Methods, compositions, and kits for analysis of enzyme activity in cells
WO2006119860A8 (de) Zellkultursystem sowie verfahren zur kultivierung einer zellkultur
Baker et al. Site-specific N-glycosylation characterization of windmill palm tree peroxidase using novel tools for analysis of plant glycopeptide mass spectrometry data
SG148027A1 (en) Methods for identifying combinations of entities as therapeutics
Bulfer et al. Crystal structure and functional analysis of homocitrate synthase, an essential enzyme in lysine biosynthesis
Gevaert et al. Applications of diagonal chromatography for proteome‐wide characterization of protein modifications and activity‐based analyses
AU3326900A (en) Ceramidase gene
Botzen et al. Degradation of HNE-modified proteins–possible role of ubiquitin
GB0409775D0 (en) Assay

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140601